Mudita Advisors LLP Sells 7,893 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Mudita Advisors LLP lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 26,707 shares of the medical research company’s stock after selling 7,893 shares during the quarter. Charles River Laboratories International makes up about 2.9% of Mudita Advisors LLP’s investment portfolio, making the stock its 11th largest position. Mudita Advisors LLP’s holdings in Charles River Laboratories International were worth $5,260,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of CRL. Allspring Global Investments Holdings LLC grew its stake in Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after acquiring an additional 509,163 shares in the last quarter. Marshall Wace LLP grew its position in shares of Charles River Laboratories International by 24.6% during the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock valued at $170,615,000 after purchasing an additional 163,056 shares in the last quarter. 1832 Asset Management L.P. bought a new stake in shares of Charles River Laboratories International in the second quarter worth about $33,053,000. Earnest Partners LLC lifted its position in shares of Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Charles River Laboratories International by 73.6% during the second quarter. The Manufacturers Life Insurance Company now owns 239,913 shares of the medical research company’s stock valued at $49,561,000 after buying an additional 101,732 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

CRL opened at $197.75 on Wednesday. The business has a fifty day moving average of $194.94 and a 200 day moving average of $205.44. The stock has a market cap of $10.11 billion, a P/E ratio of 24.75, a PEG ratio of 5.19 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period in the prior year, the firm earned $2.72 EPS. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.

Charles River Laboratories International announced that its Board of Directors has approved a share buyback program on Wednesday, August 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CRL. TD Cowen upped their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a research note on Monday, November 18th. Baird R W cut shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. Finally, Robert W. Baird dropped their price target on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and a consensus target price of $214.38.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).